Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 966

1.

Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.

Rossignol P, Duarte K, Girerd N, Karoui M, McMurray JJV, Swedberg K, van Veldhuisen DJ, Pocock S, Dickstein K, Zannad F, Pitt B.

Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1724. [Epub ahead of print]

PMID:
31919958
2.

Genetic risk and atrial fibrillation in patients with heart failure.

Kloosterman M, Santema BT, Roselli C, Nelson CP, Koekemoer A, Romaine SPR, Van Gelder IC, Lam CSP, Artola VA, Lang CC, Ng LL, Metra M, Anker S, Filippatos G, Dickstein K, Ponikowski P, van der Harst P, van der Meer P, van Veldhuisen DJ, Benjamin EJ, Voors AA, Samani NJ, Rienstra M.

Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1735. [Epub ahead of print]

PMID:
31919934
3.

Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study.

Wettersten N, Horiuchi Y, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, Taub P, Vilke GM, Barnett O, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Maisel A, Murray PT.

Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1642. [Epub ahead of print]

PMID:
31863682
4.

Selenium and outcome in heart failure.

Bomer N, Grote Beverborg N, Hoes MF, Streng KW, Vermeer M, Dokter MM, IJmker J, Anker SD, Cleland JGF, Hillege HL, Lang CC, Ng LL, Samani NJ, Tromp J, van Veldhuisen DJ, Touw DJ, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Dec 6. doi: 10.1002/ejhf.1644. [Epub ahead of print]

PMID:
31808274
5.

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.

Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, Böhm M, McMurray JJV, Wikstrand J, Anker SD, van Veldhuisen DJ, Manzano L, von Lueder TG, Rigby AS, Andersson B, Kjekshus J, Wedel H, Ruschitzka F, Cleland JGF, Damman K, Redon J, Coats AJS; Beta-Blockers in Heart Failure Collaborative Group.

J Am Coll Cardiol. 2019 Dec 10;74(23):2893-2904. doi: 10.1016/j.jacc.2019.09.059.

6.

Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.

Pandhi P, Ter Maaten JM, Emmens JE, Struck J, Bergmann A, Cleland JG, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Cotter G, Davison B, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1693. [Epub ahead of print]

PMID:
31797505
7.

The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach.

Hoes MF, Tromp J, Ouwerkerk W, Bomer N, Oberdorf-Maass SU, Samani NJ, Ng LL, Lang CC, van der Harst P, Hillege H, Anker SD, Metra M, van Veldhuisen DJ, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1674. [Epub ahead of print]

PMID:
31797504
8.

Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study.

Ferreira JP, Ouwerkerk W, Tromp J, Ng L, Dickstein K, Anker S, Filippatos G, Cleland JG, Metra M, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Dec 2. doi: 10.1002/ejhf.1654. [Epub ahead of print]

PMID:
31793144
9.

Doppler gradients, valve area and ventricular function in pregnant women with aortic or pulmonary valve disease: Left versus right.

Siegmund AS, Pieper PG, Mulder BJM, Sieswerda GT, van Dijk APJ, Roos-Hesselink JW, Jongbloed MRM, Konings TC, Bouma BJ, Groen H, Sollie-Szarynska KM, Kampman MAM, Bilardo CM, van Veldhuisen DJ, Aalberts JJJ.

Int J Cardiol. 2019 Nov 16. pii: S0167-5273(18)36330-7. doi: 10.1016/j.ijcard.2019.11.118. [Epub ahead of print]

PMID:
31785953
10.

B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure.

Wettersten N, Horiuchi Y, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, Taub P, Vilke GM, Barnett O, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Murray PT, Maisel A.

Eur J Heart Fail. 2019 Dec;21(12):1553-1560. doi: 10.1002/ejhf.1627. Epub 2019 Nov 25.

PMID:
31769140
11.

Myocardial adiposity in heart failure with preserved ejection fraction: the plot thickens.

van Woerden G, van Veldhuisen DJ, Rienstra M, Westenbrink BD.

Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1653. [Epub ahead of print] No abstract available.

PMID:
31769136
12.

Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study.

Kloosterman M, Crijns HJGM, Mulder BA, Groenveld HF, Van Veldhuisen DJ, Rienstra M, Van Gelder IC.

Europace. 2019 Nov 20. pii: euz300. doi: 10.1093/europace/euz300. [Epub ahead of print]

PMID:
31747018
13.

Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF.

McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer NK, Vardeny O, Claggett B, Jhund PS, Solomon SD.

Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044491. [Epub ahead of print]

PMID:
31736337
14.

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.

Nauta JF, Hummel YM, Tromp J, Ouwerkerk W, van der Meer P, Jin X, Lam CSP, Bax JJ, Metra M, Samani NJ, Ponikowski P, Dickstein K, Anker SD, Lang CC, Ng LL, Zannad F, Filippatos GS, van Veldhuisen DJ, van Melle JP, Voors AA.

Eur J Heart Fail. 2019 Nov 11. doi: 10.1002/ejhf.1632. [Epub ahead of print]

PMID:
31713324
15.

Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF.

Kobayashi M, Voors AA, Girerd N, Billotte M, Anker SD, Cleland JG, Lang CC, Ng LL, van Veldhuisen DJ, Dickstein K, Metra M, Duarte K, Rossignol P, Zannad F, Ferreira JP.

Eur J Intern Med. 2019 Nov 7. pii: S0953-6205(19)30354-1. doi: 10.1016/j.ejim.2019.10.017. [Epub ahead of print]

PMID:
31708361
16.

Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.

Cao TH, Jones DJL, Voors AA, Quinn PA, Sandhu JK, Chan DCS, Parry HM, Mohan M, Mordi IR, Sama IE, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Lang CC, Ng LL.

Eur J Heart Fail. 2019 Nov 6. doi: 10.1002/ejhf.1608. [Epub ahead of print]

PMID:
31692186
17.

Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.

Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P.

JACC Heart Fail. 2019 Nov;7(11):970-979. doi: 10.1016/j.jchf.2019.07.010. Epub 2019 Oct 9.

PMID:
31606364
18.

Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial.

Monzo L, Ferreira JP, Abreu P, Szumski A, Böhm M, McMurray JJV, Pitt B, Swedberg K, van Veldhuisen DJ, Girerd N, Vincent J, Zannad F, Rossignol P.

J Hypertens. 2019 Oct 3. doi: 10.1097/HJH.0000000000002275. [Epub ahead of print]

PMID:
31584516
19.

Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.

van der Wal HH, Grote Beverborg N, Dickstein K, Anker SD, Lang CC, Ng LL, van Veldhuisen DJ, Voors AA, van der Meer P.

Eur Heart J. 2019 Nov 21;40(44):3616-3625. doi: 10.1093/eurheartj/ehz680.

20.

Effect of Systolic Blood Pressure on Left Ventricular Structure and Function: A Mendelian Randomization Study.

Hendriks T, Said MA, Janssen LMA, van der Ende MY, van Veldhuisen DJ, Verweij N, van der Harst P.

Hypertension. 2019 Oct;74(4):826-832. doi: 10.1161/HYPERTENSIONAHA.119.12679. Epub 2019 Sep 3.

PMID:
31476911
21.

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees.

N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.

PMID:
31475794
22.

Patients with heart failure with and without a history of stroke in the Netherlands: a secondary analysis of psychosocial, behavioural and clinical outcomes up to three years from the COACH trial.

Ski CF, van der Wal MHL, Le Grande M, van Veldhuisen DJ, Lesman-Leegte I, Thompson DR, Middleton S, Cameron J, Jaarsma T.

BMJ Open. 2019 Aug 27;9(8):e025525. doi: 10.1136/bmjopen-2018-025525.

23.

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.

Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B.

Eur Heart J. 2019 Nov 21;40(44):3593-3602. doi: 10.1093/eurheartj/ehz427.

24.

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.

Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP; ASIAN-HF investigators, Voors AA.

Lancet. 2019 Oct 5;394(10205):1254-1263. doi: 10.1016/S0140-6736(19)31792-1. Epub 2019 Aug 22.

PMID:
31447116
25.

Residual confounding in observational studies: new data from the old DIG trial.

Boorsma EM, Rienstra M, van Veldhuisen DJ, van der Meer P.

Eur Heart J. 2019 Oct 21;40(40):3342-3344. doi: 10.1093/eurheartj/ehz527. No abstract available.

PMID:
31390005
26.

Cancer and heart disease: associations and relations.

de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ.

Eur J Heart Fail. 2019 Dec;21(12):1515-1525. doi: 10.1002/ejhf.1539. Epub 2019 Jul 18.

PMID:
31321851
27.

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.

Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators.

JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10.

PMID:
31302043
28.

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.

Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA.

Clin Res Cardiol. 2019 Jul 1. doi: 10.1007/s00392-019-01513-y. [Epub ahead of print]

PMID:
31263996
29.

Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies.

Grote Beverborg N, van der Wal HH, Klip IT, Anker SD, Cleland J, Dickstein K, van Veldhuisen DJ, Voors AA, van der Meer P.

JAMA Cardiol. 2019 Jul 1;4(7):696-701. doi: 10.1001/jamacardio.2019.1739.

PMID:
31188392
30.

Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS).

Murray PT, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, Horiuchi Y, Clopton P, Taub P, Vilke GM, Barnett O, McDonald K, Mahon N, NuÑez J, Briguori C, Passino C, Maisel A.

J Card Fail. 2019 Aug;25(8):654-665. doi: 10.1016/j.cardfail.2019.05.009. Epub 2019 May 22.

PMID:
31128242
31.

Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure.

Emmens JE, Ter Maaten JM, Damman K, van Veldhuisen DJ, de Boer RA, Struck J, Bergmann A, Sama IE, Streng KW, Anker SD, Dickstein K, Lang CC, Metra M, Samani NJ, Ng LL, Voors AA.

Circ Heart Fail. 2019 May;12(5):e005544. doi: 10.1161/CIRCHEARTFAILURE.118.005544.

PMID:
31091993
32.

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.

Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Aug;21(8):965-973. doi: 10.1002/ejhf.1482. Epub 2019 May 14.

PMID:
31087601
33.

Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.

Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradović V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ; GENETIC-AF Trial Investigators.

JACC Heart Fail. 2019 Jul;7(7):586-598. doi: 10.1016/j.jchf.2019.04.004. Epub 2019 Apr 29.

PMID:
31042551
34.

Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.

Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD.

Eur J Heart Fail. 2019 Jul;21(7):862-873. doi: 10.1002/ejhf.1473. Epub 2019 Apr 29.

PMID:
31033127
35.

Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.

Greenberg B, Neaton JD, Anker SD, Byra WM, Cleland JGF, Deng H, Fu M, La Police DA, Lam CSP, Mehra MR, Nessel CC, Spiro TE, van Veldhuisen DJ, Vanden Boom CM, Zannad F.

JAMA Cardiol. 2019 Jun 1;4(6):515-523. doi: 10.1001/jamacardio.2019.1049.

PMID:
31017637
36.

Agreement of 2D transthoracic echocardiography with cardiovascular magnetic resonance imaging after ST-elevation myocardial infarction.

Hendriks T, Al Ali L, Maagdenberg CG, van Melle JP, Hummel YM, Oudkerk M, van Veldhuisen DJ, Nijveldt R, van der Horst ICC, Lipsic E, van der Harst P.

Eur J Radiol. 2019 May;114:6-13. doi: 10.1016/j.ejrad.2019.02.039. Epub 2019 Feb 28.

PMID:
31005178
37.

Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction.

Wolsk E, Kaye D, Komtebedde J, Shah SJ, Borlaug BA, Burkhoff D, Kitzman DW, Lam CSP, van Veldhuisen DJ, Ponikowski P, Petrie MC, Hassager C, Møller JE, Gustafsson F.

JACC Heart Fail. 2019 Apr;7(4):321-332. doi: 10.1016/j.jchf.2019.01.006. Epub 2019 Mar 6.

PMID:
30852235
38.

Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.

Ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, Ng LL, Dickstein K, Metra M, Samani NJ, Romaine SPR, Cleland J, Girerd N, Lang CC, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2019 Jun;21(6):732-743. doi: 10.1002/ejhf.1437. Epub 2019 Mar 6.

PMID:
30843353
39.

Pregnancy in women with pre-existent ischaemic heart disease: a systematic review with individualised patient data.

Lameijer H, Burchill LJ, Baris L, Ruys TP, Roos-Hesselink JW, Mulder BJM, Silversides CK, van Veldhuisen DJ, Pieper PG.

Heart. 2019 Jun;105(11):873-880. doi: 10.1136/heartjnl-2018-314364. Epub 2019 Feb 21. Review.

PMID:
30792240
40.

The year in cardiology 2018: heart failure.

Cleland JGF, van Veldhuisen DJ, Ponikowski P.

Eur Heart J. 2019 Feb 21;40(8):651-661. doi: 10.1093/eurheartj/ehz010. No abstract available.

PMID:
30778534
41.

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.

Ferreira JP, Abreu P, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ, Vincent J, Lins K, Rossignol P, Pitt B, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):345-351. doi: 10.1002/ejhf.1400. Epub 2019 Feb 15.

PMID:
30768732
42.

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.

van den Berg MP, Mulder BA, Klaassen SHC, Maass AH, van Veldhuisen DJ, van der Meer P, Nienhuis HLA, Hazenberg BPC, Rienstra M.

Eur Heart J. 2019 Apr 21;40(16):1287-1293. doi: 10.1093/eurheartj/ehz057.

43.

Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?

Rienstra M, Kotecha D, van Veldhuisen DJ.

Eur J Heart Fail. 2019 Apr;21(4):480-481. doi: 10.1002/ejhf.1425. Epub 2019 Jan 30. No abstract available.

PMID:
30698314
44.

Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study.

De With RR, Rienstra M, Smit MD, Weijs B, Zwartkruis VW, Hobbelt AH, Alings M, Tijssen JGP, Brügemann J, Geelhoed B, Hillege HL, Tukkie R, Hemels ME, Tieleman RG, Ranchor AV, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC.

Europace. 2019 Apr 1;21(4):563-571. doi: 10.1093/europace/euy311.

PMID:
30629160
45.

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.

Mordi IR, Santema BT, Kloosterman M, Choy AM, Rienstra M, van Gelder I, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Metra M, Ng LL, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Voors AA, Lang CC.

Clin Res Cardiol. 2019 Jul;108(7):797-805. doi: 10.1007/s00392-018-1409-x. Epub 2019 Jan 4.

46.

Rapid right-sided deterioration in heart failure with preserved ejection fraction.

Gorter TM, van Veldhuisen DJ, Voors AA.

Eur Heart J. 2019 Feb 21;40(8):699-702. doi: 10.1093/eurheartj/ehy900. No abstract available.

PMID:
30608519
47.

Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate.

Chin KL, Collier T, Pocock S, Pitt B, McMurray JJV, van Veldhuisen DJ, Swedberg K, Vincent J, Zannad F, Liew D.

Clin Res Cardiol. 2019 Jul;108(7):806-814. doi: 10.1007/s00392-018-1410-4. Epub 2019 Jan 2.

48.

Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, Samani NJ, Cleland JG, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Feb;21(2):218-226. doi: 10.1002/ejhf.1380. Epub 2019 Jan 1.

PMID:
30600578
49.

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P.

Eur Heart J. 2018 Dec 21;39(48):4269-4276. doi: 10.1093/eurheartj/ehy712.

PMID:
30551207
50.

Discussion forum response to Canepa et al.

Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ.

Eur Heart J. 2019 Feb 21;40(8):705-706. doi: 10.1093/eurheartj/ehy796. No abstract available.

PMID:
30500882

Supplemental Content

Loading ...
Support Center